Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 7 - Studien 61 bis 70 von insgesamt 88
- Rekrutierung läuftPhase III, Multicenter, Open label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide versus investigator choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma
- Rekrutierung läuftA Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)
- Rekrutierung läuftConstructing and validation of a robust, affordable, and widely applicable real-world outcome predictor for risk-tailored therapy for DLBCL patients in the German healthcare system
- Rekrutierung läuftOhrakupressur bei Patienten mit Multiplem Myelom - eine randomisierte kontrollierte Studie
- Rekrutierung läuftInternational, multicenter, non-interventional PASS study to evaluatemthe effectiveness and safety of elranatamab in patients with relapsed/refractory multiple myelom treated in real world settings
- Rekrutierung läuftPhase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Rekrutierung läuftA Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy
- Rekrutierung läuftA Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma
- Rekrutierung läuftA Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2Inhibitor ABBV-453 given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple MyelomaMolekulare Marker
- Rekrutierung läuftA Phase I clinical trial to assess safety and tolerability of autologous ROR1 CAR-T cells in ROR1+ tumorsIndikationenMolekulare Marker